08:00 | Registration |
| Session: Biomarker Profiling and Discovery |
| |
09:00 | | Keynote Presentation Context Specific Qualification of Biomarkers in Diseases. Andrea Peracino, Vice President, Fondazione Giovanni Lorenzini Medical Science Foundation, Italy
There is a need for consensus criteria for validation and qualification of the integrated approach in the specific context of use of the biomarkers. The necessity and the advantages of an open discussion and peer-to-peer dialogue among clinicians, biochemists, mathematicians, and health organizations, bio-imaging, bioinformatics, regulatory, health economics, and industry experts, are even more confirmed. |
|
09:30 | Signaling Networks in Cancer Tissues: Protein Analysis of Formalin-Fixed Tissue Sections Michael Pawlak, Head, University of Tuebingen, Germany
A high throughput analysis of FFPE tissue sections using Reverse-phase Protein Arrays was established that allows the generation of complex signalling profiles. Molecular profiles from more than 150 signaling proteins will be presented. Their use for defining pharmacodynamic and patient stratification biomarkers will be discussed. |
10:00 | Genome-Scale Quantitative Tumour Proteomics for Cancer Biomarkers Discovery Metodi Metodiev, Biological Safety Officer, University of Essex, United Kingdom
Genome-scale quantitative tumour proteomics for cancer biomarkers discovery. |
10:30 | Coffee Break and Networking in the Exhibition Hall |
11:15 | Harmonization and Standardization of CNS Biomarkers Rivka Ravid, Brain Bank Consultant, Royal Dutch Academy of Sciences, Netherlands
|
11:45 | Cerebrospinal Fluid Biomarkers for Neurodegeneration Niklas Mattsson, Medical Doctor & Researcher, Sahlgrens University Hospital, Sweden
Cerebrospinal fluid (CSF) biomarkers may be used for molecular diagnostics of several diseases, including Alzheimer's disease. They are used in clinical routine, research and drug development. To support the standardization of CSF biomarkers, a global external quality control program was recently initiated. |
12:15 | Lunch and Networking in the Exhibition Hall |
13:30 | Poster Session |
14:15 | Mode of Action Analysis and Biomarker Discovery Using Mass Spectrometry-Based Phosphoproteomics Technologies Andreas Jenne, CEO, Kinaxo Biotechnologies, Germany
Global quantitative phosphoproteomics facilitates detailed mode-of-action analysis of targeted drugs and discovery of regulated protein phosphorylations that can function as response prediction biomarkers for patient stratification. |
14:45 | Quantitative Proteomics For Biomarker Discovery and Validation: Prostate Cancer Case Study Stephen Pennington, Professor, University College Dublin, Ireland
There is an important need for clinically relevant biomarkers which will improve the diagnosis and the management of patients with prostate cancer. Here a strategy integrating label-free LC-MS based protein biomarker discovery with subsequent multiplexed validation by multiple reaction monitoring MS that is directed to the development of biomarkers of clinical utility for prostate
cancer will be described. |
15:15 | Coffee Break and Networking in the Exhibition Hall |
| Session: Biomarkers in Clinical Applications |
| |
16:00 | Networks as Markers – A New Concept That Has Entered Clinics. Serhiy Souchelnytskyi, Associate Professor, Karolinska Institutet, Sweden
Reaction of a body to a treatment defines successfulness of the treatment. Dynamic Response Networks predicting such a reaction enter clinics. DRNets for management of breast cancer is an example of clinical applications. |
16:30 | Translating Lymphoma Gene Expression Signatures into Routine Clinical Biomarkers Alison Banham, Reader, University of Oxford, United Kingdom
Gene expression profiling has identified clinically relevant subtypes of diffuse large B-cell lymphoma with distinct mechanisms of disease pathogenesis. Routine biomarkers are required to guide patient stratification for the next generation of molecular targeted therapies. |
17:00 | Close of Day One |